---
figid: PMC7757414__fonc-10-599933-g001
figlink: pmc/articles/PMC7757414/figure/f1/
number: F1
caption: 'Targeted therapies available and in development in Acute Myeloid Leukemia
  (AML). Many tyrosine kinases inhibitors are either currently available or in development.
  These include: Fms-Like Tyrosine Kinase 3 (FLT3) inhibitors (such as sorafenib,
  quizartinib, gilteritinib, crenolanib), pan-kinase inhibitors (including midostaurin),
  FLT3 and KIT inhibitors (including pacritinib), Janus Kinase-2 (JAK2) and interleukine-1
  Receptor (IL-1R) Associated Kinases 1/4 (IRAK1/4) inhibitors, the IRAK4 inhibitor
  Ca-4948, the JAK2 inhibitor ruxolitinib, NRAS, KRAS and MAP Kinases (MAPK) inhibitors
  (such as vemurafenib, pazopanib, tivozanib), mTOR inhibitors (everolimus and dactolisib),
  TEC kinases inhibitors (including ibrutinib), and vascular and endothelial growth
  factor receptor (VEGFR) inhibitor cediranib. Several targeted-drugs are available,
  or in development, for transcription factors: ivosidenib, an Isocitrate Deshydrogenase-1
  (IDH1) inhibitor, enasidenib, an IDH2 inhibitor, azacytidine, decitabine, guadecitabine
  as hypomethylated agents, the histone deacetylase vorinostat and panobinostat, DS-3201b,
  a zeste 2 polycomb repressive complex 2 subunit (EZH2) inhibitor, pinometostat,
  a DOT1-like histone lysine methyltransferase (DOT1L) inhibitor, crizotinib, the
  Bcl6 Corepressor (BCOR) inhibitor, OTX015, a cyclin-dependent kinase 9/bromodomain
  and extraterminal (CDK9/BET) inhibitor, and elesclomol, a TP53 inhibitor. Selinexor
  inhibits the XPO1 exporter, which inhibits leukemic activity of mutated NPM1 proteins.
  Glasdegib inhibits smoothened multi-transmembrane (SMO), a member of the Hedgehog
  pathway. Tagraxofusp inhibits CD123, whereas IMGN632 transports chemotherapy through
  CD123 internalization, as does gemtuzumab ozogamicin and SGN-CD33A through CD33.
  Venetoclax inhibits the BCL2 anti-apoptotic protein. Several microenvironment targeted
  drug are in development: etomoxir inhibits fatty acid oxidation metabolism, tigecycline
  inhibits mitochondrial heterocellular transfer, thus inhibiting drug resistance
  exchange, ulocuplumab inhibits CXCR4/CXCL12 interaction from inducing leukemia myeloid
  cell migration, mirabegron, an agonist for sympathetic neuropathy β3-adrenergic
  receptor (β3-AR), and cavtratin, the NO synthase inhibitor.'
pmcid: PMC7757414
papertitle: 'Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development
  and Pre-Clinical Therapeutics.'
reftext: Xavier Roussel, et al. Front Oncol. 2020;10:599933.
pmc_ranked_result_index: '117305'
pathway_score: 0.8753137
filename: fonc-10-599933-g001.jpg
figtitle: Targeted therapies available and in development in Acute Myeloid Leukemia
  (AML)
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7757414__fonc-10-599933-g001.html
  '@type': Dataset
  description: 'Targeted therapies available and in development in Acute Myeloid Leukemia
    (AML). Many tyrosine kinases inhibitors are either currently available or in development.
    These include: Fms-Like Tyrosine Kinase 3 (FLT3) inhibitors (such as sorafenib,
    quizartinib, gilteritinib, crenolanib), pan-kinase inhibitors (including midostaurin),
    FLT3 and KIT inhibitors (including pacritinib), Janus Kinase-2 (JAK2) and interleukine-1
    Receptor (IL-1R) Associated Kinases 1/4 (IRAK1/4) inhibitors, the IRAK4 inhibitor
    Ca-4948, the JAK2 inhibitor ruxolitinib, NRAS, KRAS and MAP Kinases (MAPK) inhibitors
    (such as vemurafenib, pazopanib, tivozanib), mTOR inhibitors (everolimus and dactolisib),
    TEC kinases inhibitors (including ibrutinib), and vascular and endothelial growth
    factor receptor (VEGFR) inhibitor cediranib. Several targeted-drugs are available,
    or in development, for transcription factors: ivosidenib, an Isocitrate Deshydrogenase-1
    (IDH1) inhibitor, enasidenib, an IDH2 inhibitor, azacytidine, decitabine, guadecitabine
    as hypomethylated agents, the histone deacetylase vorinostat and panobinostat,
    DS-3201b, a zeste 2 polycomb repressive complex 2 subunit (EZH2) inhibitor, pinometostat,
    a DOT1-like histone lysine methyltransferase (DOT1L) inhibitor, crizotinib, the
    Bcl6 Corepressor (BCOR) inhibitor, OTX015, a cyclin-dependent kinase 9/bromodomain
    and extraterminal (CDK9/BET) inhibitor, and elesclomol, a TP53 inhibitor. Selinexor
    inhibits the XPO1 exporter, which inhibits leukemic activity of mutated NPM1 proteins.
    Glasdegib inhibits smoothened multi-transmembrane (SMO), a member of the Hedgehog
    pathway. Tagraxofusp inhibits CD123, whereas IMGN632 transports chemotherapy through
    CD123 internalization, as does gemtuzumab ozogamicin and SGN-CD33A through CD33.
    Venetoclax inhibits the BCL2 anti-apoptotic protein. Several microenvironment
    targeted drug are in development: etomoxir inhibits fatty acid oxidation metabolism,
    tigecycline inhibits mitochondrial heterocellular transfer, thus inhibiting drug
    resistance exchange, ulocuplumab inhibits CXCR4/CXCL12 interaction from inducing
    leukemia myeloid cell migration, mirabegron, an agonist for sympathetic neuropathy
    β3-adrenergic receptor (β3-AR), and cavtratin, the NO synthase inhibitor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - SMO
  - IRAK4
  - IRAK1
  - TEC
  - HRAS
  - KRAS
  - NRAS
  - MAPK14
  - MAPK3
  - MAPK8
  - MAPK11
  - MAPK13
  - MAPK12
  - MAPK1
  - MAPK9
  - MAPK10
  - MTOR
  - CD33
  - CDK9
  - CD48
  - BCL2
  - IDH2
  - IDH1
  - EZH2
  - BCOR
  - MET
  - MAGEE1
  - TP53
  - DNMT3A
  - XPO1
  - IL3RA
  - IL1RAP
  - IL1R1
  - IL1RL1
  - FLT3
  - KIT
  - JAK2
  - FLT1
  - FLT4
  - KDR
  - CXCR4
  - Midostaurin
  - Sorafenib
  - Quizartinib
  - Gilternitinib
  - Cytarabine
  - Anthracycline
  - Crenolanib
  - Pacritinib
  - Cediranib
  - Entospletinib
  - Tyrosine
  - Ibrutinib
  - Everolimus
  - Vemurafenib
  - Pazopanib
  - Tivozanib
  - Tigecycline
  - ozogamicin
  - OTX015
  - Co123
  - Ivosidenib
  - Crizotinib
  - Azacytidine
  - Decitabine
  - Guadecitabine
  - 1RAP O
  - AML
genes:
- word: SMO
  symbol: SMO
  source: hgnc_symbol
  hgnc_symbol: SMO
  entrez: '6608'
- word: IRAK1/4
  symbol: IRAK4
  source: hgnc_symbol
  hgnc_symbol: IRAK4
  entrez: '51135'
- word: IRAK1/4
  symbol: IRAK1
  source: hgnc_symbol
  hgnc_symbol: IRAK1
  entrez: '3654'
- word: TEC
  symbol: TEC
  source: hgnc_symbol
  hgnc_symbol: TEC
  entrez: '7006'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: CD33
  symbol: CD33
  source: hgnc_symbol
  hgnc_symbol: CD33
  entrez: '945'
- word: CDK9/BET
  symbol: CDK9
  source: hgnc_symbol
  hgnc_symbol: CDK9
  entrez: '1025'
- word: blast
  symbol: BLAST
  source: hgnc_alias_symbol
  hgnc_symbol: CD48
  entrez: '962'
- word: BCL2
  symbol: BCL2
  source: hgnc_symbol
  hgnc_symbol: BCL2
  entrez: '596'
- word: IDH1/2
  symbol: IDH2
  source: hgnc_symbol
  hgnc_symbol: IDH2
  entrez: '3418'
- word: IDH1/2
  symbol: IDH1
  source: hgnc_symbol
  hgnc_symbol: IDH1
  entrez: '3417'
- word: EZH2
  symbol: EZH2
  source: hgnc_symbol
  hgnc_symbol: EZH2
  entrez: '2146'
- word: BCOR
  symbol: BCOR
  source: hgnc_symbol
  hgnc_symbol: BCOR
  entrez: '54880'
- word: МЕТ
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: damages
  symbol: DAMAGE
  source: hgnc_alias_symbol
  hgnc_symbol: MAGEE1
  entrez: '57692'
- word: TP53
  symbol: TP53
  source: hgnc_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: DNMT3A
  symbol: DNMT3A
  source: hgnc_symbol
  hgnc_symbol: DNMT3A
  entrez: '1788'
- word: XPO1
  symbol: XPO1
  source: hgnc_symbol
  hgnc_symbol: XPO1
  entrez: '7514'
- word: CD33
  symbol: CD33
  source: hgnc_symbol
  hgnc_symbol: CD33
  entrez: '945'
- word: CD123
  symbol: CD123
  source: hgnc_alias_symbol
  hgnc_symbol: IL3RA
  entrez: '3563'
- word: IL-1RAP
  symbol: IL1RAP
  source: hgnc_symbol
  hgnc_symbol: IL1RAP
  entrez: '3556'
- word: IL-1R
  symbol: IL1R
  source: hgnc_prev_symbol
  hgnc_symbol: IL1R1
  entrez: '3554'
- word: IL-1RAP
  symbol: IL1RAP
  source: hgnc_symbol
  hgnc_symbol: IL1RAP
  entrez: '3556'
- word: IL-33R
  symbol: IL33R
  source: hgnc_alias_symbol
  hgnc_symbol: IL1RL1
  entrez: '9173'
- word: IL-1RAP
  symbol: IL1RAP
  source: hgnc_symbol
  hgnc_symbol: IL1RAP
  entrez: '3556'
- word: IL-1RAP()
  symbol: IL1RAP
  source: hgnc_symbol
  hgnc_symbol: IL1RAP
  entrez: '3556'
- word: FLT3
  symbol: FLT3
  source: hgnc_symbol
  hgnc_symbol: FLT3
  entrez: '2322'
- word: '*FLT3'
  symbol: FLT3
  source: hgnc_symbol
  hgnc_symbol: FLT3
  entrez: '2322'
- word: IL-1RAP)
  symbol: IL1RAP
  source: hgnc_symbol
  hgnc_symbol: IL1RAP
  entrez: '3556'
- word: KIT
  symbol: KIT
  source: hgnc_symbol
  hgnc_symbol: KIT
  entrez: '3815'
- word: JAK2
  symbol: JAK2
  source: hgnc_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: '*JAK2'
  symbol: JAK2
  source: hgnc_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: CXCR4-----
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
chemicals:
- word: Midostaurin
  source: MESH
  identifier: C059539
- word: Sorafenib
  source: MESH
  identifier: C471405
- word: Quizartinib
  source: MESH
  identifier: C544967
- word: Gilternitinib
  source: ''
  identifier: ''
- word: Cytarabine
  source: MESH
  identifier: D003561
- word: Anthracycline
  source: MESH
  identifier: D018943
- word: Crenolanib
  source: MESH
  identifier: C577197
- word: Pacritinib
  source: MESH
  identifier: C561234
- word: Cediranib
  source: MESH
  identifier: C500926
- word: Entospletinib
  source: ''
  identifier: ''
- word: Tyrosine
  source: ''
  identifier: ''
- word: Ibrutinib
  source: MESH
  identifier: C551803
- word: Everolimus
  source: MESH
  identifier: C107135
- word: Vemurafenib
  source: MESH
  identifier: C551177
- word: Pazopanib
  source: MESH
  identifier: C516667
- word: Tivozanib
  source: MESH
  identifier: C553176
- word: Tigecycline
  source: MESH
  identifier: C119092
- word: ozogamicin
  source: MESH
  identifier: C406061
- word: OTX015
  source: MESH
  identifier: C530377
- word: Co123
  source: MESH
  identifier: C492712
- word: Ivosidenib
  source: ''
  identifier: ''
- word: Crizotinib
  source: MESH
  identifier: C551994
- word: Azacytidine
  source: MESH
  identifier: D001374
- word: Decitabine
  source: MESH
  identifier: C014347
- word: Guadecitabine
  source: ''
  identifier: ''
- word: 1RAP O
  source: MESH
  identifier: C052497
diseases:
- word: AML
  source: MESH
  identifier: D015470
figid_alias: PMC7757414__F1
redirect_from: /figures/PMC7757414__F1
figtype: Figure
---
